TARA
Protara Therapeutics, Inc. (NASDAQ)
Healthcare — Biotechnology
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.
Price History
Fundamentals
| Market Cap | $227.63M |
| P/E Ratio (TTM) | - |
| Forward P/E | -2.46 |
| EPS (TTM) | $-1.36 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -37.27% |
| Debt/Equity | 1.69 |
| Recommendation | Strong Buy 1.3 |
| Analyst Target | $26.57 |
| Analysts | 7 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 61.1 |
| Beta | 1.45 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $7.82 |
| 52-Week Low | $2.80 |
| 50-Day Avg | $4.64 |
| 200-Day Avg | $5.30 |
| Avg Volume | 732.3K |
| Volume | 9.2K |
Performance Analysis
BULLISHTARA shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Jul 02, 2026 13:33 UTC
Back to Screener Export Report